PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

被引:527
|
作者
Glaviano, Antonino [1 ]
Foo, Aaron S. C. [2 ]
Lam, Hiu Y. [3 ,4 ]
Yap, Kenneth C. H. [3 ,4 ]
Jacot, William [5 ]
Jones, Robert H. [6 ,7 ]
Eng, Huiyan [2 ,3 ]
Nair, Madhumathy G. [8 ]
Makvandi, Pooyan [9 ]
Geoerger, Birgit [10 ]
Kulke, Matthew H. [11 ,12 ]
Baird, Richard D. [13 ]
Prabhu, Jyothi S. [8 ]
Carbone, Daniela [1 ]
Pecoraro, Camilla [1 ]
Teh, Daniel B. L. [14 ,15 ,16 ]
Sethi, Gautam [2 ,3 ]
Cavalieri, Vincenzo [1 ]
Lin, Kevin H. [17 ]
Javidi-Sharifi, Nathalie R. [17 ]
Toska, Eneda [18 ]
Davids, Matthew S. [17 ]
Brown, Jennifer R. [17 ]
Diana, Patrizia [1 ]
Stebbing, Justin [19 ]
Fruman, David A. [20 ]
Kumar, Alan P. [2 ,3 ]
机构
[1] Univ Palermo, Dept Biol Chem & Pharmaceut Sci & Technol, I-90123 Palermo, Italy
[2] Natl Univ Singapore, Natl Univ Singapore Hosp, Dept Surg, Singapore, Singapore
[3] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117600, Singapore
[4] Natl Univ Singapore, Yong Loo Lin Sch Med, NUS Ctr Canc Res N2CR, Singapore 119077, Singapore
[5] Univ Montpellier, Inst Canc Montpellier, Dept Med Oncol, Inserm U1194, Montpellier, France
[6] Cardiff Univ, Museum Ave, Cardiff CF10 3AX, Wales
[7] Velindre Canc Ctr, Museum Ave, Cardiff CF10 3AX, Wales
[8] St Johns Res Inst, Div Mol Med, St Johns Med Coll, Bangalore 560034, Karnataka, India
[9] Wenzhou Med Univ, Quzhou Peoples Hosp, Quzhou Affiliated Hosp, Quzhou 324000, Zhejiang, Peoples R China
[10] Univ Paris Saclay, Gustave Roussy Canc Ctr, Dept Pediat & Adolescent Oncol, Inserm U1015, Paris, France
[11] Boston Univ, Sect Hematol & Med Oncol, Boston, MA USA
[12] Boston Med Ctr, Boston, MA USA
[13] Canc Res UK Cambridge Ctr, Hills Rd, Cambridge CB2 0QQ, England
[14] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore
[15] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore, Singapore
[16] Natl Univ Singapore, Neurobiol Programme, Singapore, Singapore
[17] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[18] Johns Hopkins Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD USA
[19] Imperial Coll London, Div Canc, Hammersmith Campus,Cane Rd, London W12 0NN, England
[20] Univ Calif Irvine, Dept Mol Biol & Biochem, 216 Sprague Hall, Irvine, CA USA
关键词
PI3K; AKT; mTORC pathway; Pan PI3K inhibitors; Isoform-specific PI3K inhibitors; Dual PI3K; mTOR inhibitors; AKT inhibitors; Allosteric mTOR inhibitors; ATP-competitive mTOR inhibitors; Bi-steric mTOR inhibitors; PDK1; inhibitors; Cancer; RENAL-CELL CARCINOMA; FOXO TRANSCRIPTION FACTORS; ADVANCED BREAST-CANCER; PHASE-I TRIAL; PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR; NONFUNCTIONAL NEUROENDOCRINE TUMORS; CHRONIC LYMPHOCYTIC-LEUKEMIA; INTRAVENOUS PI3K INHIBITOR; PROTEIN-COUPLED RECEPTORS; HEPATOCYTE GROWTH-FACTOR;
D O I
10.1186/s12943-023-01827-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell cycle progression. Growth factor signalling to transcription factors in the PAM axis is highly regulated by multiple cross-interactions with several other signaling pathways, and dysregulation of signal transduction can predispose to cancer development. The PAM axis is the most frequently activated signaling pathway in human cancer and is often implicated in resistance to anticancer therapies. Dysfunction of components of this pathway such as hyperactivity of PI3K, loss of function of PTEN, and gain-of-function of AKT, are notorious drivers of treatment resistance and disease progression in cancer. In this review we highlight the major dysregulations in the PAM signaling pathway in cancer, and discuss the results of PI3K, AKT and mTOR inhibitors as monotherapy and in co-administation with other antineoplastic agents in clinical trials as a strategy for overcoming treatment resistance. Finally, the major mechanisms of resistance to PAM signaling targeted therapies, including PAM signaling in immunology and immunotherapies are also discussed.
引用
收藏
页数:37
相关论文
共 50 条
  • [31] Targeting the PI3K/AKT/mTOR pathway in ovarian cancer
    Musa, Fernanda
    Schneider, Robert
    TRANSLATIONAL CANCER RESEARCH, 2015, 4 (01) : 97 - 106
  • [32] Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors
    Welker, Mark E.
    Kulik, George
    BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (14) : 4063 - 4091
  • [33] The PI3K/AKT/mTOR signaling pathway in osteoarthritis: a narrative review
    Sun, K.
    Luo, J.
    Guo, J.
    Yao, X.
    Jing, X.
    Guo, F.
    OSTEOARTHRITIS AND CARTILAGE, 2020, 28 (04) : 400 - 409
  • [34] The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism
    Su, Hengchuan
    Gu, Yanyun
    Li, Fengying
    Wang, Qidi
    Huang, Baoxing
    Jin, Xiaolong
    Ning, Guang
    Sun, Fukang
    PLOS ONE, 2013, 8 (04):
  • [35] PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia
    Xie, Youbang
    Shi, Xuefeng
    Sheng, Kuo
    Han, Guoxiong
    Li, Wenqian
    Zhao, Qiangqiang
    Jiang, Baili
    Feng, Jianming
    Li, Jianping
    Gu, Yuhai
    MOLECULAR MEDICINE REPORTS, 2019, 19 (02) : 783 - 791
  • [36] Targeting the PI3K/Akt/mTOR Signaling Pathway: Applications of Nanotechnology
    Serej, Forough Alemi
    Pourhassan-Moghaddam, Mohammad
    Kalan, Mohammad Ebrahimi
    Mehdipour, Ahmad
    Serej, Zeynab Aliyari
    Ebrahimi-Kalan, Abbas
    CRESCENT JOURNAL OF MEDICAL AND BIOLOGICAL SCIENCES, 2018, 5 (01): : 7 - 13
  • [37] PI3K/AKT/mTOR pathway in angiogenesis
    Karar, Jayashree
    Maity, Amit
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2011, 4
  • [38] PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?
    Abraham, Jame
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 51 - 68
  • [39] Overview of the PI3K/Akt/mTOR pathway
    Dennis, P. A.
    ANNALS OF ONCOLOGY, 2008, 19 : 21 - 21
  • [40] The PI3K/AKT/mTOR interactive pathway
    Ersahin, Tulin
    Tuncbag, Nurcan
    Cetin-Atalay, Rengul
    MOLECULAR BIOSYSTEMS, 2015, 11 (07) : 1946 - 1954